Rezdiffra (resmetirom) is Madrigal Pharmaceuticals' once-daily oral thyroid hormone receptor-beta (THR-β) selective agonist, the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. It won accelerated approval in March 2024 on histologic data from MAESTRO-NASH, and its launch reshaped a category that had nothing approved before it.
At EASL 2026 in Barcelona, Madrigal dropped eight posters covering cardiovascular markers (Lp(a), LDL-C, ApoB reductions), the ANTICIPATE-NASH portal-hypertension risk score in compensated F4c MASH cirrhosis, and combination-therapy work pairing resmetirom with Sagimet's FASN inhibitor denifanstat. The drug now sits at the center of every MASH combination question, including with the GLP-1/glucagon dual agonists like survodutide and pemvidutide; MetaVia's June 2026 vanoglipel + resmetirom combination poster is a representative example.
Stories here cover Rezdiffra real-world uptake, label-expansion work, and combination data. See #resmetirom, #thr-beta, and #mash for adjacent threads.
Hengrui Pharma disclosed Saturday August 22, 2026 that China's Center for Drug Evaluation (CDE) granted implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatitis. The CDE implied license is a Chinese regulatory instrument that provides approval to initiate human clinical trials in China under a simplified pathway (similar in function to a US Investigational New Drug application, though procedurally different). HRS-4729's specific molecular mechanism has not been publicly disclosed in detail; the MAFLD/hepatitis indication placement suggests likely mechanisms include FGF21 analog, thyroid hormone receptor beta agonist, or a novel liver-target mechanism. The disclosure extends Hengrui's cardiometabolic pipeline beyond its existing ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist licensed ex-China to Kailera Therapeutics for global Phase 3 initiation in H1 2027) into the growing MASH commercial category. MASH commercial market context: the category is anchored by Madrigal Pharmaceuticals' Rezdiffra (resmetirom, a thyroid hormone receptor beta agonist and the first FDA-approved MASH drug, approved March 2024) and Novo Nordisk's Wegovy (semaglutide 2.4 mg received FDA accelerated approval for non-cirrhotic MASH with moderate-to-advanced fibrosis in August 2025). The Hengrui advance into MAFLD/hepatitis positions the company for a potential fourth cardiometabolic franchise beyond obesity, type 2 diabetes, and cardiovascular disease.
Madrigal Pharmaceuticals delivered eight Rezdiffra (resmetirom) poster presentations at EASL 2026 today. Key data: secondary analysis of MAESTRO-NASH and MAESTRO-NAFLD-1 documented Rezdiffra-driven improvements in cardiovascular lipid risk markers (Lp(a), LDL-C, ApoB); a two-year analysis in patients with compensated MASH cirrhosis (F4c) showed meaningful improvement in ANTICIPATE-NASH risk scores, a validated marker for clinically significant portal hypertension. Real-world effectiveness analyses and noninvasive biomarker plus machine-learning models for predicting MASH and fibrosis improvement rounded out the presentation slate. Rezdiffra (resmetirom) — a thyroid hormone receptor β agonist small molecule, not a peptide — was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The compensated MASH cirrhosis (F4c) data extend the case toward an indication where the GLP-1/glucagon peptide programs (pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) are also competing.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
Madrigal Pharmaceuticals announced May 20 that multiple abstracts from its Rezdiffra (resmetirom) development and real-world evidence programs will be presented at EASL 2026 in Barcelona. Headline analyses include cardiovascular risk markers — secondary analysis of Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 examining improvements in Lp(a), LDL-C, and ApoB — and portal hypertension risk improvement in compensated MASH cirrhosis (F4c) measured by ANTICIPATE-NASH risk scores. Real-world evidence and noninvasive biomarker analyses round out the slate. Rezdiffra (a thyroid hormone receptor β agonist, not a peptide) was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The EASL data extend the case toward compensated MASH cirrhosis and cardiovascular outcomes — a competitive context for the GLP-1/glucagon peptide programs (semaglutide ESSENCE, pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) running on parallel tracks.